secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001785530-25-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q1 net loss $18.1M; cash $92M; WTX-124 data/FDA in H2 2025
--------------------------------------------------------------------------------

- Net loss of $18.1M in Q1 2025 vs $16.2M in Q1 2024; R&D spend $13.1M.
- Cash and equivalents $92.0M as of March 31, 2025; runway into Q4 2026.
- WTX-124 Phase 1/1b on track for interim data and FDA regulatory discussions in H2 2025.
- First patient dosed in WTX-330 Phase 1b/2 trial; initial Phase 1 data showed clinical activity and tolerability.
- INDUCER T cell engager development candidate expected by end of Q2 2025; PREDATOR masking shown to silence peripheral activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553025000013/0001785530-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553025000013/howl-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001785530-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer